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TOPIC HIGHLIGHT
Hepatitis C virus: Promising discoveries and new treatments
2016 Hepatitis C virus: Global view
Abstract
Despite advances in therapy, hepatitis C virus (HCV) 
infection remains an important global health issue. It is 
estimated that a significant part of the world population 
is chronically infected with the virus, and many of those 
affected may develop cirrhosis or liver cancer. The virus 
shows considerable variability, a characteristic that 
directly interferes with disease treatment. The response 
to treatment varies according to HCV genotype and 
subtype. The continuous generation of variants 
(quasispecies) allows the virus to escape control by 
antivirals. Historically, the combination of ribavirin and 
interferon therapy has represented the only treatment 
option for the disease. Currently, several new treatment 
options are emerging and are available to a large part 
of the affected population. In addition, the search for 
new substances with antiviral activity against HCV 
continues, promising future improvements in treatment. 
Researchers should consider the mutation capacity of 
the virus and the other variables that affect treatment 
success.
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Core tip: In recent years, new treatments for hepatitis 
C have been approved and represent a major advance-
ment in this field. However, there are limitations that 
should be considered, and research for new treatments 
must continue. The objective of this review is to 
demonstrate the breakthroughs that have occurred and 
to discuss future developments.
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INTRODUCTION
Hepatitis C virus (HCV) infection is an important cause 
of cirrhosis and hepatocellular carcinoma worldwide[1-3]. 
It is very dangerous due to the breakthrough of long-
term asymptomatic HCV[4].
HCV is transmitted through exposure to infected 
blood and blood products. HCV infection can be spread 
through blood transfusion, injection drug use, sexual 
intercourse, surgery, and tattooing[2,5]. HCV infection 
is defined as the presence of HCV RNA and anti-HCV 
antibodies in the serum or plasma; a positive HCV 
antibody test indicates exposure to HCV and could 
represent a current or past infection. A positive HCV 
RNA test indicates a current HCV infection[2].
It is estimated that 130-150 million people globally 
have chronic hepatitis C infection, and a significant 
number of those who are chronically infected will 
develop liver cirrhosis or liver cancer. According to 
the World Health Organization, 350000 to 500000 
people die each year from hepatitis C-related liver 
diseases. The most affected regions are Central and 
East Asia and North Africa, although the virus is found 
worldwide[6].
The natural history of HCV is influenced by a wide 
variety of factors. Host factors include age at infection, 
gender, race, obesity, steatosis, insulin resistance/
diabetes, genetics, alanine aminotransferase levels 
and exercise. Viral factors include HCV RNA level, 
quasispecies/genotype, coinfection with hepatitis B 
virus and coinfection with human immunodeficiency 
virus. Environmental factors include alcohol use, 
cigarette use, cannabis use, caffeine consumption and 
herbal product use[1].
Approximately 15%-45% of infected persons 
spontaneously clear the virus within 6 mo of infection 
without any treatment, and the remaining 55%-85% 
of persons may progress to persistent chronic infection. 
It is estimated that the risk of developing cirrhosis of 
the liver within 20 years is 15%-30% in those with 
chronic HCV infection[6], and the risk of developing 
hepatocellular carcinoma is 1%-4% per year[1].
Acute HCV hepatitis in immunocompetent individuals 
is generally asymptomatic, but immunocompromised 
hosts (HIV infection) experience lymphoplasmatic portal 
inflammation, interface hepatitis, necroinflammatory 
lobular changes, moderately advanced fibrosis or rapid 
progression to fibrosis over a period of time[7].
Chronic hepatitis is defined as the persistence of 
infection for at least 6 mo after the onset of infection 
and is characterized by necroinflammation accompanied 
by a variable degree of fibrosis[7], end-stage liver 
disease and hepatocellular carcinoma[1].
The main extrahepatic manifestations in patients 
with HCV infection are immune- and inflammatory-
related. Immune-related extrahepatic manifestations 
include mixed cryoglobulinemia, cryoglobulinemic 
vasculitis, B-cell NHL, Sicca syndrome, arthralgia/
myalgia, autoantibody production (i.e., cryoglobulins, 
rheumatoid factor, and antinuclear, anticardiolipin, 
antithyroid and anti-smooth muscle antibodies), 
polyarthritis nodosa, monoclonal gammopathies, and 
immune thrombocytopenia. Inflammatory-related 
extrahepatic manifestations consist of type 2 diabetes 
mellitus, insulin resistance, glomerulonephritis, 
renal insufficiency, fatigue, cognitive impairment, 
depression, impaired quality of life, polyarthritis/
fibromyalgia, and cardiovascular disorders (i.e., stroke 
and ischemic heart disease)[8]. Recent studies have 
suggested that HCV infection leads to increased risk 
of developing cardiovascular diseases and has been 
linked to increased risk of mortality caused by these 
diseases[9].
Several studies have considered the existence of 
occult HCV infection (viral RNA identified in hepatocytes 
but absent in serum). Although occult HCV infection is 
challenged by some researchers and is characterized 
by others as a milder condition than chronic hepatitis C, 
it is necessary to consider its existence because some 
studies have shown links between occult HCV infection 
and liver cirrhosis and hepatocellular carcinoma. In 
addition, due to the emergence of new treatment 
options, all possibilities should be considered, and 
special attention should be given to transfusion centers 
and patient risk groups[10,11].
HCV 
HCV, classified in the family Flaviviridae, is an en-
veloped, single stranded positive sense RNA virus 
with a genome approximately 9600 nucleotides 
in length[12], encoding approximately 3000 amino 
acids[13]. Most of the genome is composed of a single 
open reading frame that encodes ten proteins: three 
structural proteins (core, E1, E2) and seven non-
structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, 
NS5B)[13]. Most recently, an HCV protein named F was 
reported[14,15]. 
The most variable region of the genome is the 
region that codes the membrane glycoproteins E1 
and E2[16]. Within the E2 gene, two hypervariable 
regions (HVR1 and HVR2) are described that show 
less sequence homology between isolates, with 50% 
identity[17]. Non-structural protein genes, such as the 
core gene, are some of the most conserved on the 
genome[12]. Within the 5’-NCR region, the most distant 
related isolates present 90% sequence identity[18,19].
The host immune system, large population sizes, 
short generation times and high replication rates 
are the factors that lead to the genetic variability 
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of HCV[20]. Seven genetic lineages (genotypes 1 to 
7) are recognized. These genotypes are subdivided 
into closely related sub-types differing from each 
other by 15% in nucleotide sequences[21]. Differences 
between the complete genomes occur at 31%-33% of 
nucleotide sites[22]. In Western countries, subtypes 1a, 
1b and 3a are believed to cause the majority of HCV 
infections and are widely distributed[12]. 
For example, only 10%-20% of patients chronically 
infected with HCV genotype 1 show complete and 
permanent disappearance of the virus when treated 
with IFN-α alone, and 40%-50% experience successful 
treatment when treated with a combined therapy 
(INF-α/RBV). When patients infected with genotypes 
2 or 3 are treated with monotherapy or combined 
therapy, higher successful treatment rates are 
observed (50% and 70%-80%, respectively)[23,24].
The mutation rate of HCV is estimated to be 
2.5 × 10-5 mutations per nucleotide per genome 
replication[25], which is one of the highest rates for RNA 
viruses, including retroviruses[26]. Recombination also 
increases the genetic variability of HCV. Inter and intra 
genotypic recombinations have already been reported 
in various geographic locations, and the existence of 
intergenotypic recombination forms has also been 
reported[27,28]. Genotype 2 is considered to be present 
in most of the cases of recombinant forms, but other 
genotypes, except for genotype 4 and 7, also exhibit 
recombinant forms[29]. At the same time, the mutation 
rate may negatively affect the viability of viral 
populations. In a situation called lethal mutagenesis, 
a nucleotide sequence loses its information when the 
error rate transcends a tolerable limit[30].
Due to the high replication rate of HCV, an extensive 
number of variants are continuously produced during 
infection. These variants are closely related to each 
other but differ in nucleotide sequence, circulating as 
a complex population known as quasispecies. This 
population is able to rapidly adapt to a constantly 
changing environment[31,32]. This adaptation could 
lead to the coexistence of diverse variants in infected 
patients, creating an environment for intra and 
inter quasispecies interactions[33]. As a result of 
the continuous generation of variants, some of the 
variants may adapt to this changing environment and 
escape control by antiviral drugs[34]. Predominant and 
minor quasispecies can be transmitted in humans[35,36] 
and experimentally infected chimpanzees[37,38]. It 
is important to highlight that the HCV population 
fluctuates in patients during therapy, suggesting that 
HCV quasispecies may follow different evolution paths 
in different patients[39].
Host genetics are also indicated as a factor that could 
influence HCV evolution and treatment response[40]. 
For example, single nucleotide polymorphisms near 
the IL-28B gene appear to be associated with a low 
genetic variability in the NS3 coding region of the HCV 
genome[41]. 
EVOLUTION OF HCV TREATMENT
Since HCV treatment began in the early 1990s, 
treatment options have improved. Interferon alpha 
(IFN-α) was the first pan-genotypic option, with 
sustained virologic response (SVR) rates of 8%-21%[42]. 
Subsequently, the guanosine analogue ribavirin (RBV) 
was combined with IFN-α, which enhanced SVR rates 
to 40%. Then, pegylated IFN-α (PEG-IFN-α) associated 
with RBV improved SVR rates from 42% to 52%[43-45]. 
In 2011, the first wave of direct-acting antiviral 
agents (DAAs), NS3/4A protease inhibitors telaprevir 
(TVR) and boceprevir (BOC), became available. The 
association of these protease inhibitors with PEG-
IFN-α/RBV improved SVR rates among patients with 
HCV genotype 1 infection. In treatment-naïve patients, 
the addition of TVR or BOC to PEG/RBV leads to an 
SVR increase of approximately 30%. Despite this 
improvement in SVR, these drugs were associated with 
serious adverse events (AEs) and low tolerance. More 
recently, a second wave of new DAAs allowed IFN-
free, highly effective regimens. SVR can be achieved 
in more than 90% of treated patients via IFN-free 
regimens, with minimal AEs and high tolerability[46-49]. 
Unlike the nonspecific IFN-α-based and PEG-IFN-
α-based therapies, DAAs target various proteins 
involved in HCV replication. In addition, most of these 
agents are specific to one or more genotypes. The 
classes of DAAs include NS3/4A protease inhibitors, 
NS5A inhibitors (nucleotides and non-nucleotide 
analogues), and NS5B polymerase inhibitors. During 
HCV replication, NS3/4A serine protease is required for 
self-cleavage, the NS5A region plays an important role 
in viral replication and assembly, and the NS5B region 
encodes RNA polymerase. Some of these drugs were 
initially combined with PEG-IFN-α and RBV, including 
the protease inhibitors TVR, BOC and simeprevir (SMV) 
and the NS5B polymerase inhibitor sofosbuvir (SOF). 
However, these regimens were still associated with 
PEG-IFN-α and RBV AEs and low tolerability[50-52]. 
All-oral treatment options followed this development, 
some associated with RBV and some not, including 
the combinations of SMV and SOF and SOF and NS5A 
inhibitor daclatasvir, the 3D regimen (paritaprevir/
ritonavir/ombitasvir, co-administered with dasabuvir), 
and SOF plus ledipasvir. In recent years, more drugs 
have been designed, including grazoprevir, elbasvir, 
asunaprevir, beclabuvir, faldaprevir, and deleobuvir[52,53]. 
Drug options and their respective mechanisms and 
genotype sensitivity are shown in Table 1. The com-
bined therapies increased SVR rates and tolerability and 
shortened treatment duration[52]. Treatment options for 
HCV infection, ranging from IFN-based regimens to new 
all-oral combinations, are presented in Table 2. 
Although HCV treatment has clearly improved 
since the introduction of DAAs, some challenges 
remain. Some populations remain difficult to treat, 
such as cirrhotic patients, prior non-responders, 
genotype 3-infected patients and patients with renal 
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ties with respect to replication cycle, biology, and 
genetic organization[77]. Many studies have sought 
new compounds with antiviral activity from natural 
products. For example, a study performed in Brazil[78] 
investigated the antiviral activity of several marine 
invertebrates and the microorganisms isolated from 
them. This study showed that an extract produced 
from the Bacillus genus, isolated from the sponge 
Petromica citrina, has potential antiviral activity 
and demonstrated an inhibition of 98% and a high 
selectivity index during viral adsorption. Another 
study performed in Brazil[79] described the antiviral 
activity, with 99% of inhibition and a selectivity index 
greater than 200 µmol/L, of compounds produced 
from Streptomyces chartreusis, a termite-associated 
bacterium.
Extracts from plants have also been investigated 
as potential producers of novel compounds that could 
be used to treat HCV. For example, one study[80] 
that screened Brazilian plant species described four 
compounds-a natural alkaloid isolated from Maytrenus 
ilicifolia and three other compounds from Peperomia 
blanda-that could drastically reduce RNA levels and 
viral protein levels during HCV replication. 
In addition to the importance of screening, and 
due to the number of extracts that could be evaluated, 
others research studies have already identified mole-
cules from natural sources belonging to different 
chemical families that have antiviral activity that affects 
different stages of the HCV life cycle[81]. Some active 
molecules cited in this review[81] include naringenin, 
extracted from grapefruit, quercetin, extracted from 
Embelia ribes, honokiol, extracted from Magnolia 
grandiflora; and others.
The polyphenols excoecariphenol D and corilagin, 
both isolated from the Chinese mangrove plant (Exco­
ecaria agallocha), were shown to potentially inhibit HCV 
RNA replication in cells[82]. The monoterpene camphor, 
isolated from Ocimun basilicum, was identified as a 
potential virucidal, suggesting that the mechanism 
of action of this compound acts directly on the viral 
particle[83].
Another compound known as silymarin, a flavonoid 
extract from the milk thistle of Silybum marianum, 
showed promising antiviral activity, both in vitro and in 
vivo at different stages of HCV replication: entry of the 
HCV into the cell hosts, RNA and protein expression 
and in the secretion of infectious viral particles[84]. 
This compound has also been reported[85] to potently 
reduce HCV RNA levels in vivo when administered 
intravenously, and to dose-dependently inhibit the HCV 
3a core gene[86]. 
CONCLUSION 
In recent years, treatment for hepatitis C has made 
considerable advances, represented by an increase 
in SVR rates, reduction of treatment duration and 
reduction of AEs. However, despite these advances, the 
impairment[52,60]. In this group, the combination of 
grazoprevir and elbasvir appears to result in high SVR 
rates in the short-term[72]. Most of the DAAs have 
drug-to-drug interactions, requiring the substitution 
or suspension of some medications during HCV 
treatment[9]. The development of viral drug-induced 
resistance may compromise actual and future treat-
ment options. Finally, some DAA regimens have 
significant cost barriers and are not fully available 
worldwide[52,73].
DAAs are currently too expensive for governments 
worldwide, especially in some low- and middle-income 
countries. Nevertheless, price decreases have already 
been announced for some of these drugs. As patents 
expire, high drug costs will be reduced, although this 
process will take several decades. This prospect offers 
some hope that universal access to the treatment 
might be possible and that DAAs will be optimally used 
to reduce HCV-related mortality and incidence in low- 
and middle-income countries[74,75].
ANTIVIRAL RESEARCH
Despite the progress of current DAAs in terms of SVR 
and treatment tolerability, difficult to treat populations 
and the emergence of resistant virus species indicate 
the continued need for research into new treatment 
options.
Some studies indicate that caffeine has the potential 
to improve liver function in patients chronically infected 
with HCV. Through in vitro research, it was possible to 
verify that caffeine may be an important new agent for 
anti-HCV therapies due to its efficient inhibition of HCV 
replication at non-toxic concentrations[76].
Many researchers use the bovine viral diarrhea 
virus (BVDV), another Flavivirus member, as a sur-
rogate model in HCV studies because propagation 
in vitro is difficult, and HCV and BVDV share similari-
Table 1  Drugs for hepatitis C virus treatment
Mechanism of action Drug Genotype
Protease inhibitor Telaprevir 1
Boceprevir 1
Simeprevir 1
Paritaprevir 1, 4
Grazoprevir 1, 4
Asunaprevir1 1
ABT-4501 1
Faldaprevir1 1
NS5A inhibitors Daclatasvir 1, 3
Ombitasvir 1, 4
Ledipasvir 1, 4, 5, 6
Elbasvir 1, 4
Velpatasvir1 4
NS5B inhibitors
   Nucleotide-analogue Sofosbuvir 1, 2, 3, 4, 5, 6
   Non-nucleoside analogue Dasabuvir 1
Beclabuvir1 1
1Non-FDA approved drugs.
Bastos JCS et al . HCV: Promising discoveries and new treatments
Table 2  Treatments for hepatitis C virus infection
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limitations of available treatments must be addressed. 
The difficult to treat populations and the emergence 
of resistant virus species indicate the continued need 
for research into new treatment options. Therefore, 
research must continue so that new substances 
with potential antiviral activity against this virus are 
identified and the limitations of existing treatments 
can be overcome. In addition to treatment, we must 
always consider the importance of prevention and the 
need for global pacts that will allow these treatments 
to be made available throughout the world.
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